Carol Ashe
Director/Board Member at APTOSE BIOSCIENCES INC.
Net worth: 1 857 $ as of 29/04/2024
Carol Ashe active positions
Companies | Position | Start | End |
---|---|---|---|
APTOSE BIOSCIENCES INC. | Director/Board Member | 14/08/2018 | - |
Independent Dir/Board Member | 14/08/2018 | - | |
ELICIO THERAPEUTICS, INC. | Director/Board Member | 31/07/2020 | - |
Independent Dir/Board Member | 31/07/2020 | - | |
New York Genome Center
New York Genome Center Miscellaneous Commercial ServicesCommercial Services New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY. | Corporate Officer/Principal | 31/12/2013 | - |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Director/Board Member | 31/12/2019 | - |
Independent Dir/Board Member | 31/12/2019 | - |
Career history of Carol Ashe
Former positions of Carol Ashe
Companies | Position | Start | End |
---|---|---|---|
ENDO INTERNATIONAL PLC | Corporate Officer/Principal | 31/12/2010 | 31/12/2012 |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Private Equity Investor | - | 29/03/2010 |
GSK PLC | Corporate Officer/Principal | 31/12/2006 | 31/12/2007 |
Training of Carol Ashe
The Pennsylvania State University | Undergraduate Degree |
Villanova University School of Law | Graduate Degree |
Statistics
International
United States | 7 |
Canada | 2 |
Ireland | 2 |
Operational
Director/Board Member | 3 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 3 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
APTOSE BIOSCIENCES INC. | Health Technology |
GSK PLC | Health Technology |
ELICIO THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
New York Genome Center
New York Genome Center Miscellaneous Commercial ServicesCommercial Services New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY. | Commercial Services |
Endo International Plc
Endo International Plc Pharmaceuticals: MajorHealth Technology Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland. | Health Technology |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Carol Ashe
- Experience